Rise Therapeutics, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) grant to fund the development of the novel engineered probiotic for the treatment of inflammatory bowel disease (IBD).

Virtici, LLC announced today the award of supplemental funds to the ASCEND Accelerator Hub. The ASCEND Accelerator Hub is an NIH-funded consortium led by Virtici and includes 10 of the leading research institutions in the Western States (Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming).

Rockville, MD. Rise Therapeutics announced today it was awarded a $2 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Dental and Craniofacial Research (NIDCR). Grant funds will be used to develop a novel, immunologically enhanced probiotic-based therapeutic for the treatment of Sjögren’s syndrome (SS).

Celdara Medical, LLC today announced that the first DRIVEN Accelerator Hub Participant Company, CairnSurgical, Inc., has closed a Series A investment led by Morningside Group.

Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million.

Virtici, LLC today announced the launch of an online resource database for biomedical entrepreneurs: http://bioentrepreneurresources.com. This database was developed in collaboration with the DRIVEN Accelerator Hub, a parallel NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI).